title: Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study.
abstract: Reducing the amount of Helicobacter pylori in the stomach by selective bacterial-bacterial cell interaction was sought as an effective and novel method for combating the stomach pathogen. Lactobacillus reuteri DSM17648 was identified as a highly specific binding antagonist to H. pylori among more than 700 wild-type strains of Lactobacillus species. Applying a stringent screening procedure, the strain DSM17648 was identified as selective binder to H. pylori cells under in vivo gastric conditions. The strain DSM17648 co-aggregates the pathogen in vivo and in vitro. The specific co-aggregation occurs between Lact. reuteri DSM17648 and different H. pylori strains and serotypes, as well as H. heilmannii, but not with Campylobacter jejuni or other commensal oral and intestinal bacteria. Lact. reuteri DSM17648 was shown in a proof-of-concept single-blinded, randomized, placebo-controlled pilot study to significantly reduce the load of H. pylori in healthy yet infected adults. Reducing the amount of H. pylori in the stomach by selective bacterial-bacterial cell interaction might be an effective and novel method for combating the stomach pathogen. Lact. reuteri DSM17648 might prove useful as an adhesion blocker in antibiotic-free H. pylori therapies.
authors.affiliation: ORGANOBALANCE GmbH, Gustav-Meyer-Allee 25, 13355, Berlin, Germany.
authors.forename: Caterina
authors.initials: C
authors.lastname: Holz
authors.forename: Andreas
authors.initials: A
authors.lastname: Busjahn
authors.forename: Heidrun
authors.initials: H
authors.lastname: Mehling
authors.forename: Stefanie
authors.initials: S
authors.lastname: Arya
authors.forename: Mewes
authors.initials: M
authors.lastname: Boettner
authors.forename: Hajar
authors.initials: H
authors.lastname: Habibi
authors.forename: Christine
authors.initials: C
authors.lastname: Lang
mesh_terms: D000293:Adolescent; D058491:Bacterial Load; D016123:Campylobacter jejuni / Q000472:pathogenicity; D018592:Cross-Over Studies; D000069196:Gastrointestinal Microbiome; D016481:Helicobacter Infections / Q000628:therapy*; D016480:Helicobacter pylori / Q000472:pathogenicity*; D006801:Humans; D052200:Limosilactobacillus reuteri / Q000502:physiology*; D016014:Linear Models; D010865:Pilot Projects; D019936:Probiotics / Q000008:administration & dosage; D016037:Single-Blind Method; D013270:Stomach / Q000382:microbiology